Janux Therapeutics, Inc. (JANX)
NASDAQ • Healthcare
Last close at September 21, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 44 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc. is a NASDAQ-listed biotechnology company developing cancer therapies, with $10.0 million of revenue in FY2025. The company centers its work on its proprietary Tumor Activated T Cell Engager, or TRACTr, platform, which is designed to activate the body's T cells against tumors, and it operates from San Diego, California.
Today's Snapshot
JANX ended yesterday 2.5% up at 17.01.
Trading Volume
Below 10d avg (1.0M)
701.8K
vs S&P 500 Today
Outperforming Market
+1.04%
Updated: September 22, 2026 at 12:30 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$16.50 - $17.55Sell
- RSI (14)46.11Neutral
- Stochastic %K (14, 3, 3)18.27Buy
- MACD Level (12, 26)-0.09Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.